Retroperitoneal surgery in patients with nonseminomatous testicular cancer and minimal residual tumor
✍ Scribed by Dr. Hanne Qvist; Sophie Dorothea Fosså; Sigurd Ous; Hans H. Lien; Anna E. Stenwig; Karl-Erik Giercksky
- Publisher
- John Wiley and Sons
- Year
- 1992
- Tongue
- English
- Weight
- 382 KB
- Volume
- 50
- Category
- Article
- ISSN
- 0022-4790
No coin nor oath required. For personal study only.
✦ Synopsis
In the period 1980-1991, 78 patients with advanced nonseminomatous testicular cancer underwent retroperitoneal lymphadenectomy for postchemotherapy residual masses <2 cm. To decrease the frequency of "dry ejaculation" in these patients with no or limited residual disease, the extent of dissection was reduced during the period, with bilateral dissections (49 cases, 1980-1986) being initially replaced by unilateral procedures ( I9 cases, 1983-1 990) and subsequently by nerve-sparing techniques ( 10 cases, 1990-1991). As expected, a higher total number of lymph nodes was found in the retroperitoneal specimens after bilateral (44 (13-100)) than after unilateral (21 (7-35)) and nerve-sparing (18 (7-1)
procedures. The number of lymph nodes with pathological changes was low, with 3 (1-16) after bilateral, 2 (1-9) after unilateral, and 2 ( 1 4 ) after nervesparing operations. Histological examination revealed only necrosis/ fibrosis in 65% of the patients, elements of mature teratoma in 28%, and remnants of viable malignant tumor in 6%. There were no major postoperative complications. "Dry ejaculation" was reported by 84% of the patients with bilateral operations, but was generally avoided after the unilateral (16%) and nerve-sparing (nil) procedures. After a mean follow-up of 83 (5-138) months, 6 patients have developed a recurrence, only one of them primarily in the retroperitoneal space. It is concluded that in patients with minimal residual retroperitoneal tumor, postchemotherapy lymphadenectomy using a unilateral or nerve-sparing technique seems to offer an effective therapeutic alternative with acceptable postoperative morbidity and preserved ejaculation. 0 1992 WiIey-Liss. Inc.
📜 SIMILAR VOLUMES
Between 1978 and 1982 the sexual functions of 54 patients with a nonseminomatous testicular tumor stage I1 or I11 were assessed before and after treatment with surgery and combination chemotherapy. Two years after completing therapy 54 % of the patients experienced sexual functional disorders. Great
53 patients were treated with cisplatinvinblastine-bleomycin chemotherapy because of advanced nonseminomatous testicular tumor (NSTT). After the chemotherapy, the serum tumor markers were back to normal in 41 patients, of whom 35 were eligible for surgical removal of the residual tumor. In four pati
Thirty-eight patients with nonseminomatous testicular cancer were treated with cis-platinum, bleomycin, and vinblastine in combination without a prolonged maintenance phase. Twentysix patients with Stage Ill disease were treated. Seventy-six percent of those patients treated achieved complete remiss